您当前的位置：
首页 >
文章列表页 >
Cost-utility analysis of anlotinib combined with penpulimab in first-line treatment of unresectable hepatocellular carcinoma
更新时间：2026-02-11

    • Cost-utility analysis of anlotinib combined with penpulimab in first-line treatment of unresectable hepatocellular carcinoma

    • “Based on APOLLO research data, experts established a partitioned survival model to evaluate the economic feasibility of first-line treatment of uHCC with anlotinib combined with pembrolizumab and sorafenib, providing reference for China's health system.”
    • ZHONGGUO YAOFANG   Vol. 37, Issue 3, Pages: 344-349(2026)

    • DOI：10.6039/j.issn.1001-0408.2026.03.12    

      CLC： R956;R979.1

    • Received：16 September 2025，

      Revised：2026-01-22，

      Accepted：23 January 2026，

      Published：15 February 2026

    移动端阅览

  • YAN Wenying,YANG Na,ZHANG Ranran,et al.Cost-utility analysis of anlotinib combined with penpulimab in first-line treatment of unresectable hepatocellular carcinoma[J].ZHONGGUO YAOFANG,2026,37(03):344-349. DOI： 10.6039/j.issn.1001-0408.2026.03.12.

  •  
  •  

0

Views

17

下载量

0

CSCD

Alert me when the article has been cited
提交
Tools
Download
Export Citation
Share
Add to favorites
Add to my album

Related Articles

Economic evaluation of nivolumab combined with ipilimumab in the first-line treatment of unresectable malignant pleural mesothelioma
Rapid health technology assessment of deucravacitinib in the treatment of moderate-to-severe plaque psoriasis
参芪扶正注射液联合化疗用于非小细胞肺癌的药物经济学评价
EQ-5D健康量表效用积分体系的构建研究——基于我国西南地区的实证分析
成本-效用分析在我国医药卫生领域应用现状的系统综述

Related Author

SHAO Rong
SHEN Jian
JIANG Rong
DU Yi
HAN Jia
QIU Xinran
LIU Tianya
KONG Shujing

Related Institution

Dept. of Pharmacy， the Affiliated Hospital of Xuzhou Medical University
Dept. of Dermatology， the Affiliated Hospital of Xuzhou Medical University
Dept. of Anesthesiology， the Affiliated Hospital of Xuzhou Medical University
0